Back
Compare AU
Compare FANG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the NYSE FANG+ Companies (FANG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
FANG | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,897 | 77 |
Median incremental investment | $993.50 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,209.36 | $1,797.76 |
Average age group | > 35 | > 35 |
Key Summary
FANG | DRUG | |
|---|---|---|
Strategy | The Global X FANG+ ETF (FANG) seeks to track the performance of the NYSE FANG+® Index before fees, expenses, and taxes. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Micron Technology Inc (17.59 %) Broadcom Inc (11.42 %) Amazon.com Inc (9.76 %) | AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) BRL - BRAZILIAN REAL (0 %) |
Top 3 industries | Information Technology (59.88 %) Communication Services (30.22 %) Consumer Discretionary (9.90 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (100.00 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.35 % | 0.57 % |
Key Summary
FANG | DRUG | |
|---|---|---|
Issuer | ETFS | BetaShares |
Tracking index | NYSE FANG+ Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.57 % |
Price | $36.47 | $8.48 |
Size | $1.805 billion | $158.573 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 7.29 % | 1.92 % |
Market | ASX | ASX |
First listed date | 02/03/2020 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
FANG | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,897 | 77 |
Median incremental investment | $993.50 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,209.36 | $1,797.76 |
Average age group | > 35 | > 35 |
Pros and Cons
FANG | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
FANG | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |